OCT 08, 2019 5:32 PM PDT

New Type of CAR T-Cell Therapy Headed for Clinical Trials

WRITTEN BY: Carmen Leitch

Scientists have been trying to use the immune system in cancer patients’ bodies to fight cancer. The T-cells of the immune system can kill cells that are infected with a virus or that are cancerous. In CAR T-cell therapy, a patient’s T-cells are removed from the bloodstream and genetically modified in the laboratory so that they can identify cancer cells and kill them more efficiently after being reintroduced into the patient’s body. One new type of CAR T-cell therapy involves a protein associated with cancer cells, the B cell-activating factor receptor (BAFF-R). In the first test of this therapy, human leukemia and lymphoma cells that were resistant to other therapeutics were successfully eradicated. The work, which has been reported in Science Translational Medicine, will be used in a clinical trial next year on patients that experienced relapse after immunotherapy treatments.

The Food and Drug Administration has approved therapies that target a protein called CD19 on cancerous B cells, but around twenty to thirty percent of patients with leukemia and lymphoma that receive these treatments relapse. The effectiveness wears off after a few years, and their cancer comes back.

"One major obstacle to current CAR T therapy is that in up to a third of these patients, the tumor is actually smart and comes back because it has learned how to no longer express the target that's recognized by the original immunotherapy," explained the principal study author Larry Kwak, M.D., Ph.D., vice president and deputy director of City of Hope's comprehensive cancer center. "To combat that, City of Hope research has found a new, and potentially more effective, target for CAR T cell therapy against B cell leukemias and lymphomas. We plan to open a clinical trial next year using the BAFF-R CAR T cell therapy."

"This new treatment could change the face of leukemia and lymphoma treatment in the U.S. and worldwide," added Kwak,  who co-led the study with Hong Qin, Ph.D., a research professor in City of Hope's Department of Hematology & Hematopoietic Cell Transplantation.

In this work, an animal model of CD19 human tumors that resist therapy were exposed to BAFF-R CAR T-cell therapy. The researchers saw longer survival times and a reduction in tumors. There was complete tumor regression in an animal model of Burkitt lymphoma after only one treatment. In animals carrying human tumors with and without CD19 that were then given the BAFF-R CAR T-cell therapy or CD19 CAR T-cell therapy, both types of tumor cells were eradicated by the BAFF-R but not the CD19 CAR T therapy.

The researchers also compared the therapies using tumor samples from patients that had gotten CAR T treatment targeting CD19. The response to the CD19-directed therapy was diminished, while BAFF-R CAR T-cell therapy was consistently active.

"We did a head-to-head comparison of two new therapies, and our data showed that our BAFF-R CAR T therapy actually did a better job than FDA-approved CD19 CAR T therapies," Qin said. "If these results continue, we will pursue BAFF-R CAR T therapy as a kind of frontline CAR T therapy treatment for lymphoma and leukemia patients."

Sources: AAAS/Eurekalert! via City of Hope, Science Translational Medicine

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
SEP 23, 2022
Genetics & Genomics
Modern Humans Make More Neurons Than Neanderthals
SEP 23, 2022
Modern Humans Make More Neurons Than Neanderthals
Scientists have been searching for an answer to the question of what makes us human for decades. Many have looked to our ...
SEP 29, 2022
Cancer
Customer-Led Innovation: Building the CTS Xenon
SEP 29, 2022
Customer-Led Innovation: Building the CTS Xenon
How customers and R&D scientists came together across oceans and a pandemic to create a next-gen cell therapy soluti ...
OCT 06, 2022
Microbiology
A Microbial Predator Can Wreak Havoc in the Desert
OCT 06, 2022
A Microbial Predator Can Wreak Havoc in the Desert
The microorganisms of the world are in constant conflict, battling for resources and space in a microbial arms race. Som ...
OCT 14, 2022
Drug Discovery & Development
Experimental Gene Therapy Restores Night Vision in Blind Patients
OCT 14, 2022
Experimental Gene Therapy Restores Night Vision in Blind Patients
Adults with a hereditary form of childhood-onset blindness experienced dramatic improvements in night vision within days ...
NOV 11, 2022
Health & Medicine
The Biomarker That Could Help Predict Disease in Men
NOV 11, 2022
The Biomarker That Could Help Predict Disease in Men
The role of a crucial hormone called INSL3 (insulin-like peptide hormone) has been discovered, and it may help predict w ...
NOV 25, 2022
Drug Discovery & Development
Antibiotics for Acne May Impair Bone Development in Teens
NOV 25, 2022
Antibiotics for Acne May Impair Bone Development in Teens
Long-term antibiotic use to treat adolescent acne disrupts the gut microbiome and impairs bone maturation. The correspon ...
Loading Comments...